Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

Delayed Quote. Delayed  - 05/26 09:59:59 pm
13.03 USD   +0.08%
05/10 SCICLONE PHARMA : posts 1Q profit
05/10 SCICLONE PHARMA : Reports First Quarter 2016 Financial Results
04/25 SCICLONE PHARMA : To Report First Quarter 2016 Financial Results On ..
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CEST
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at debbie.cai@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on SCICLONE PHARMACEUTICALS,
05/19 SCICLONE PHARMACEUTICALS : Reports First Quarter 2016 Financial Results
05/10 SCICLONE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
05/10 SCICLONE PHARMACEUTICALS : posts 1Q profit
05/10 SCICLONE PHARMACEUTICALS : Reports First Quarter 2016 Financial Results
05/05 SCICLONE PHARMACEUTICALS : To Report First Quarter 2016 Financial Results On May..
04/25 SCICLONE PHARMACEUTICALS : To Report First Quarter 2016 Financial Results On May..
04/18 SCICLONE PHARMACEUTICALS : To Present At Needham Healthcare Conference On April ..
04/15 SCICLONE PHARMACEUTICALS : Russell Frank Co Sells 254,085 Shares of SciClone Pha..
03/30 SCICLONE PHARMACEUTICALS : To Present At Needham Healthcare Conference On April ..
03/24 SCICLONE PHARMACEUTICALS : Reports 2015 Financial Results
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials